HORMONES, HORMONE RECEPTORS AND AGING IV HORMONE REPLACEMENT IN MENOPAUSAL WOMEN

更年期女性的激素、激素受体和衰老 IV 激素替代

• 批准号: 3802251
• 负责人: S M HARMAN
• 金额: --
• 依托单位: NATIONAL INSTITUTE ON AGING
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3802251
• 关键词: 1,25 dihydroxycholecalciferol; aging; bone density; calcitonin; clinical trials; combination chemotherapy; dosage; drug adverse effect; drug interactions; estradiol; female; growth hormone releasing hormone; hormone receptor; hormone regulation /control mechanism; hormone therapy; human old age (65+); human subject; insulinlike growth factor; lipids; longitudinal human study; parathyroid hormones; placebos; postmenopause; progestins; somatotropin

Work in FY-91 has included final analysis of data and publication or preparation of manuscripts from an investigation of the interaction of age and transderman estradiol replacement at 3 different doses and placebo in postmenopausal women. We measured effects of estrogen with and without progestin on basal growth hormone GH and insulin-like growth factor I (IGF- I), GH responds to GHRH, calciotropic and gonadotropic hormone regulation, and clinical symptoms. Findings include: (1) older women remain responsive to the bone-conserving action of estrogen; (2) estrogens' action to preserve bone mass appears to be independent of any modulation of GH, IGF-I, PTH, 1-25 dihydroxy vitamin D, or calcitonin secretion; (3) older (>65 y) women have no more side effects from estrogen replacement than younger postmenopausal women and tolerate minor side effects equally well. A new study comparing interactions of oral vs. transdermal estrogen with body composition, spontaneous pulsatile GH secretion and basal and stimulated IGF-I is currently underway. Another study of long term effects of combination estrogen/progestin therapy on bone, lipids, and clinical symptoms in women >65 is underway.

1991财政年度的工作包括对数据进行最后分析， 从年龄的相互作用的调查准备手稿 和transderman雌二醇替代在3个不同的剂量和安慰剂， 绝经后妇女。 我们测量了雌激素的作用， 胰高血糖素对基础生长激素GH和胰岛素样生长因子I（IGF-1） I），GH响应GHRH、促钙激素和促性腺激素调节， 临床症状。 研究结果包括：（1）老年妇女仍然 对雌激素的骨保护作用有反应;（2）雌激素的作用 保持骨量似乎与GH的任何调节无关， IGF-I、PTH、1-25二羟维生素D或降钙素分泌;（3）老年人 （>65岁）女性没有更多的副作用，从雌激素替代品比 年轻的绝经后妇女和容忍轻微的副作用同样好。 一项新的研究比较了口服与透皮雌激素与 身体组成，自发脉冲GH分泌和基础和 目前，IGF-I的研究正在进行中。 另一项长期影响的研究 联合雌激素/孕激素治疗对骨、血脂和临床 女性>65的症状正在进行中。